6d agoSeeking AlphaBULLISH 67Earnings
Quest Diagnostics projects $11.95B-$12.05B 2026 revenue while raising EPS outlook again
Quest Diagnostics (DGX) Q2 2026 earnings call: revenue +10%, volumes +13%, Haystack MRD expansion, and raised guidance.
Archived explainer. For the current picture see today's DGX page.
Why Is QUEST DIAGNOSTICS IN (DGX) Stock Up Today?
By the Top Tier Newswire AI Desk · July 24, 2026 at 5:26 AM ET · reviewed against 11 wire stories
QUEST DIAGNOSTICS IN (DGX) is up +8.61% in the latest session. Our newswire has captured 11 stories on DGX across 6 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100).
DGX stock rose 8.61% to $227.90 on Wednesday, driven by Quest Diagnostics' second-quarter earnings beat and upward revision of full-year guidance. The company reported stronger-than-expected revenue and earnings per share, while also raising its 2026 revenue and EPS forecasts. The move reflects improved operational performance and growing demand for diagnostic services.
What Happened
Quest Diagnostics reported Q2 2026 results that exceeded expectations, with revenue growth of 10% and volume growth of 13%. The company attributed the strong performance to organic growth, operational efficiencies, and the expansion of its Haystack MRD testing. As a result, Quest raised its 2026 revenue guidance to $11.95 billion to $12.05 billion, up from a previous range of $11.78 billion to $11.9 billion. The EPS guidance was also increased to $11.05 to $11.25, above the $10.76 consensus estimate. These updates signaled confidence in the company's ability to capitalize on rising demand for diagnostic services and new product innovations.
What The Data Shows
The stock's 8.61% gain on Wednesday marked a significant intraday move, outpacing its 52-week range of $165.78 to $219.20. With a market cap of $22.9 billion, Quest Diagnostics trades at a P/E of 23.2 and has delivered 11% revenue growth in the trailing twelve months. The stock's beta of 0.57 suggests it is less volatile than the broader market. Recent insider transactions included two sales totaling $3.6 million over the past 90 days, while congressional trades showed five purchases in the same period. Social chatter on X was minimal, with only one post in the last 24 hours.
What To Watch
The company has already reported its Q2 2026 earnings and guidance. Investors should monitor the breadth of analyst coverage and any follow-up commentary from industry experts.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
DGX by the numbers
Last: $227.90Session: +8.61%Coverage: 11 stories / 6 sourcesAI sentiment: 63/100 (bullish)Mkt cap: $22.9BP/E: 23.252w: $165.78 to $219.20
The headlines behind the move
6d agoSeeking AlphaNEUTRAL 50Earnings
Quest Diagnostics Incorporated (DGX) Q2 2026 Earnings Call Transcript
Quest Diagnostics Incorporated (DGX) Q2 2026 Earnings Call July 23, 2026 8:30 AM EDTCompany ParticipantsDan Haemmerle - Interim VP of Investor Relations...
6d agoSeeking AlphaNEUTRAL 50Earnings
Quest Diagnostics Incorporated 2026 Q2 - Results - Earnings Call Presentation
2026-07-23. The following slide deck was published by Quest Diagnostics Incorporated in conjunction with their 2026 Q2 earnings call.
6d agoMarketChameleonBULLISH 73Earnings
Quest Diagnostics Ups Guidance After Strong Q2: Organic Growth Boosts EPS and Revenue Outlook July 23, 2026
Quest Diagnostics raised its 2026 revenue and EPS guidance following a robust second quarter. Organic revenue growth, operational efficiencies, and expanding partnerships have contributed to improved profitability and renewed optimism from management.
6d agoSeeking AlphaBULLISH 68Earnings
Quest Diagnostics climbs as Q2 earnings top estimates, guidance raised
Quest Diagnostics (DGX) stock jumps 11% as Q2 earnings and revenue beat estimates and 2026 guidance rises above consensus—get the key numbers and outlook...
6d agoYahoo TopBULLISH 67Earnings
Quest Diagnostics Surges After Hims- And Oura-Tied Beat
6d agoInvesting.com MarketsNEUTRAL 50General
Why is Quest Diagnostics stock surging today?
Why is Quest Diagnostics stock surging today?
6d agoMarketChameleonBULLISH 73Earnings
Quest Diagnostics Lifts 2026 Guidance as Organic Revenue Growth Accelerates to Double Digits July 23, 2026
Quest Diagnostics exceeded expectations in Q2 2026, reporting robust double-digit revenue gains and raising its full-year guidance for revenue and EPS. Gains were powered by organic growth, new diagnostics innovations, and strong demand across channels.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on DGX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier DGX move explainers: 2026-07-24 · 2026-07-23